Sandbox/v29: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
Created page with " {| style="border: 2px solid #696969;" align="center" |+ <SMALL>''Hy’s Law cases have the following three components:'' | style="background: #A5B2D6; border: 0px solid #6..."
 
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
mNo edit summary
 
Line 3: Line 3:


{| style="border: 2px solid #696969;" align="center"
{| style="border: 2px solid #696969;" align="center"
|+ <SMALL>''Hy’s Law cases have the following three components:''
|+ '''Hy’s Law cases have the following three components:'''
 
| style="font-size: 90%; padding: 1px 1px; background: #F5F5F5; width: 5px" align=left | '''1.''' || style="font-size: 90%; padding: 5px 5px; background: #DCDCDC; width: 620px;" align=left | '''The drug causes hepatocellular injury, generally shown by a higher incidence of <u>≥3xULN of ALT or AST</u> than the (nonhepatotoxic) control drug or placebo.'''
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''1.''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''The drug causes hepatocellular injury, generally shown by a higher incidence of 3-fold or greater elevations above the ULN of ALT or AST than the (nonhepatotoxic) control drug or placebo.'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | '''2.''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''Among trial subjects showing such AT elevations, often with ATs much greater than 3xULN, one or more also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (elevated serum ALP).'''
| style="font-size: 90%; padding: 1px 1px; background: #F5F5F5" align=left | '''2.''' || style="font-size: 90%; padding: 5px 5px; background: #DCDCDC; width: 620px;" | '''Among trial subjects showing such AT elevations, often with ATs much greater than 3xULN, one or more also show <u>elevation of serum TBL to >2xULN</u>, without initial findings of cholestasis (elevated serum ALP).'''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | '''3.''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of causing the observed injury.'''
| style="font-size: 90%; padding: 1px 1px; background: #F5F5F5" align=left | '''3.''' || style="font-size: 90%; padding: 5px 5px; background: #DCDCDC; width: 620px;" | '''No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of causing the observed injury.'''
 
|-
|-
|}
|}

Latest revision as of 19:12, 5 February 2014


Hy’s Law cases have the following three components:
1. The drug causes hepatocellular injury, generally shown by a higher incidence of ≥3xULN of ALT or AST than the (nonhepatotoxic) control drug or placebo.
2. Among trial subjects showing such AT elevations, often with ATs much greater than 3xULN, one or more also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (elevated serum ALP).
3. No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C; preexisting or acute liver disease; or another drug capable of causing the observed injury.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox/v29&oldid=938784"